

Edgar Filing: ISOLAGEN INC - Form 8-K

ISOLAGEN INC
Form 8-K
July 29, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

JULY 29, 2003
Date of Report (date of Earliest Event Reported)

ISOLAGEN, INC.
(Exact Name of Registrant as Specified in its Charter)

DELAWARE
(State or Other Jurisdiction of
Incorporation or Organization)

0-12666
(Commission File No.)

87-
(I.R.S. Employer)

2500 WILCREST, 5TH FLOOR, HOUSTON, TEXAS 77042
(Address of principal executive offices and zip code)

(713) 780-4754
(Registrant's telephone number, including area code)

NOT APPLICABLE
(Former name or former address, if changed from last report)

ITEM 5. OTHER EVENTS

On July 29, 2003 the Company issued a press release relating to its clinical trials. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The reader is advised to read the press release in its entirety.

[THE SIGNATURE PAGE FOLLOWS.]

Edgar Filing: ISOLAGEN INC - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ISOLAGEN, INC.

Date: July 29, 2003

By: /s/ Jeffrey W. Tomz

Chief Financial Officer

2

EXHIBIT INDEX

| EXHIBIT NO. ----- | DESCRIPTION ----- |
|----------------------|----------------------|
| 99.1 | Press Release |